Screens in diverse cell models in lab ID 2 new ALS therapeutic targets

A team of U.S. researchers have identified two proteins in the lab — PIKFYVE and SYF2 — that may each be a useful therapeutic target for treating amyotrophic lateral sclerosis (ALS). Their findings on these potential molecular targets were published in a pair of studies earlier this month. “Our…

Evotec and Celgene Partner to Screen Novel Therapies for ALS, Other Diseases

The pharmaceutical companies Evotec and Celgene will collaborate on a drug discovery and development program to identify and develop novel disease-modifying therapies for several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). The partnership will allow the screening of drug compounds developed by Celgene using Evotec’s platform of induced pluripotent…